CA2705150C - Substituted cyclopentanes having prostaglandin activity - Google Patents

Substituted cyclopentanes having prostaglandin activity Download PDF

Info

Publication number
CA2705150C
CA2705150C CA2705150A CA2705150A CA2705150C CA 2705150 C CA2705150 C CA 2705150C CA 2705150 A CA2705150 A CA 2705150A CA 2705150 A CA2705150 A CA 2705150A CA 2705150 C CA2705150 C CA 2705150C
Authority
CA
Canada
Prior art keywords
hydroxy
chloro
thiophene
carboxylic acid
cyclopentyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2705150A
Other languages
English (en)
French (fr)
Other versions
CA2705150A1 (en
Inventor
Yariv Donde
Jeremiah H. Nguyen
Robert M. Burk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40524829&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2705150(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CA2705150A1 publication Critical patent/CA2705150A1/en
Application granted granted Critical
Publication of CA2705150C publication Critical patent/CA2705150C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D333/40—Thiophene-2-carboxylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Medicinal Preparation (AREA)
CA2705150A 2007-11-09 2008-11-05 Substituted cyclopentanes having prostaglandin activity Expired - Fee Related CA2705150C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US98684907P 2007-11-09 2007-11-09
US60/986,849 2007-11-09
US12/265,062 2008-11-05
US12/265,062 US9006464B2 (en) 2007-11-09 2008-11-05 Substituted cyclopentanes having prostaglandin activity
PCT/US2008/082469 WO2009061811A1 (en) 2007-11-09 2008-11-05 Substituted cyclopentanes having prostaglanding activity

Publications (2)

Publication Number Publication Date
CA2705150A1 CA2705150A1 (en) 2009-05-14
CA2705150C true CA2705150C (en) 2016-06-14

Family

ID=40524829

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2705150A Expired - Fee Related CA2705150C (en) 2007-11-09 2008-11-05 Substituted cyclopentanes having prostaglandin activity

Country Status (21)

Country Link
US (1) US9006464B2 (enExample)
EP (1) EP2217581B1 (enExample)
JP (1) JP2011503089A (enExample)
KR (1) KR20100101097A (enExample)
CN (2) CN101952261B (enExample)
AR (1) AR069228A1 (enExample)
AU (1) AU2008324793B2 (enExample)
BR (1) BRPI0818902A2 (enExample)
CA (1) CA2705150C (enExample)
CL (1) CL2008003332A1 (enExample)
CO (1) CO6280480A2 (enExample)
DK (1) DK2217581T3 (enExample)
ES (1) ES2432058T3 (enExample)
IL (1) IL205604A (enExample)
MX (1) MX2010005105A (enExample)
NZ (1) NZ585517A (enExample)
RU (1) RU2481339C2 (enExample)
TW (1) TWI411438B (enExample)
UA (1) UA99840C2 (enExample)
WO (1) WO2009061811A1 (enExample)
ZA (1) ZA201003304B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8673341B2 (en) * 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US20100247606A1 (en) * 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
EP3991734B1 (en) 2019-06-28 2024-11-27 Gurus BioPharm Inc. Agent for the treatment of alopecia and promoting hair growth

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7012A (en) * 1850-01-15 Improvement in mowing-machines
IE37602B1 (en) * 1971-05-11 1977-08-31 Ici Ltd Cyclopentane derivatives
JPS5623984B2 (enExample) * 1973-04-19 1981-06-03
US4065472A (en) * 1975-09-29 1977-12-27 Pfizer Inc. 5-(2-Carboxythiophen-5-yl)-16-aryloxy-α-tetranor-ω-tetranorprostaglandins
GB1563201A (en) * 1975-11-05 1980-03-19 Shell Int Research Preparation of herbicidally acitve alanine derivatives
US5698598A (en) * 1995-08-04 1997-12-16 Allergan EP2 -receptor agonists as agents for lowering intraocular pressure
US5877211A (en) * 1997-11-21 1999-03-02 Allergan EP2 receptor agonists as neuroprotective agents for the eye
US6545045B1 (en) * 1998-12-24 2003-04-08 Alcon Manufacturing, Ltd. Prostaglandin E agonists for treatment of glaucoma
US7091231B2 (en) * 2004-12-10 2006-08-15 Allergan, Inc. 12-Aryl prostaglandin analogs
US7585895B2 (en) * 2005-12-06 2009-09-08 Allergan, Inc. Therapeutic substituted cyclopentanes
US7427685B2 (en) * 2005-12-06 2008-09-23 Allergan, Inc. Therapeutic substituted cyclopentanes
US7439372B2 (en) * 2006-05-03 2008-10-21 Allergan, Inc. Therapeutic compounds
WO2008094958A1 (en) 2007-02-01 2008-08-07 Allergan, Inc. Thiophene derivatives useful as medicaments for treating ocular hypertension

Also Published As

Publication number Publication date
DK2217581T3 (da) 2013-10-21
ZA201003304B (en) 2014-03-26
EP2217581B1 (en) 2013-07-31
RU2481339C2 (ru) 2013-05-10
CN101952261B (zh) 2013-06-12
TWI411438B (zh) 2013-10-11
WO2009061811A1 (en) 2009-05-14
CL2008003332A1 (es) 2011-08-12
AR069228A1 (es) 2010-01-06
CA2705150A1 (en) 2009-05-14
EP2217581A1 (en) 2010-08-18
IL205604A (en) 2014-06-30
IL205604A0 (en) 2010-11-30
US9006464B2 (en) 2015-04-14
US20090124676A1 (en) 2009-05-14
CO6280480A2 (es) 2011-05-20
UA99840C2 (ru) 2012-10-10
KR20100101097A (ko) 2010-09-16
WO2009061811A8 (en) 2009-07-02
JP2011503089A (ja) 2011-01-27
AU2008324793B2 (en) 2013-12-05
TW200934500A (en) 2009-08-16
NZ585517A (en) 2012-08-31
CN102977048A (zh) 2013-03-20
BRPI0818902A2 (pt) 2015-05-12
ES2432058T3 (es) 2013-11-29
CN101952261A (zh) 2011-01-19
MX2010005105A (es) 2010-05-27
RU2010122681A (ru) 2011-12-20
AU2008324793A1 (en) 2009-05-14

Similar Documents

Publication Publication Date Title
CA2705150C (en) Substituted cyclopentanes having prostaglandin activity
EP2526094A1 (en) Therapeutic substituted chlorocyclopentanols
PT1608309E (pt) Derivados de ácido 10,10-dialquil-prostanóico como agentes para diminuição da pressão intra-ocular
WO2009006370A1 (en) Therapeutic substituted cyclopentanes for reducing intraocular pressure
KR101561706B1 (ko) 치료제로서의 치환된 감마 락탐
US8546603B2 (en) Substituted cyclopentanes having prostaglandin activity
AU2009209330B2 (en) Substituted gamma lactams as therapeutic agents
US8455547B2 (en) Substituted cyclopentanes having prostaglandin activity
HK1181392A (en) Substituted cyclopentanes having prostaglanding activity
AU2011209770A1 (en) Therapeutically active cyclopentanes

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20131101

MKLA Lapsed

Effective date: 20211105